Drug intelligence / Profile preview

SB-10

Development stage: Preclinical
Lead developer: Spine BioPharma
Administration: Injectable

Overview

SB-10 is a non-opiate, non-surgical injectable drug developed by Spine BioPharma. It is being developed as a treatment for degenerative disc disease. Spine BioPharma secured a $13 million Series B equity financing round to support its development, and Pacira Biosciences invested $3 million in the drug in 2021, with potential for an additional $7 million based on milestones.

Targets

TGFB1 (Transforming growth factor Beta-1 proprotein)

Beyond the preview

Go deeper on SB-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB-10.

Explore the full profile